The study is a single centre, phase I, double-blind, randomized, placebo-controlled trial
that explored the safety and immunogenicity of single dose a allantoic split inactivated
seasonal influenza vaccine in healthy adults.
Biological: influenza vaccine
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT03028116
Ages eligible for Study
18 Years to 50 Years
Genders eligible for Study
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Healthy volunteers of both sexes aged 18-60 years.
Persons seronegative against A/H1N1 influenza virus, A/H3N2 and type B (with antibody titers ≤1: 10, according to hemagglutination-inhibition (HI) assay to determine).
Literate and willing to provide written informed consent.
A signed informed consent.
Available in anamnaze volunteer at any allergic reactions.
Allergic reactions to chicken proteins, or any preceding vaccination.
Acute illness with a fever (37.0 C).
Vaccination against influenza in the 2012/2013 season.
Seropositive volunteers against A/H1N1 influenza virus, A/H3N2 and type B (with antibody titers greater than 1:10 according HI).
Current or recent (within two weeks of enrollment) acute respiratory illness with or without fever.
Hypersensitivity after previous administration of any vaccine.
History of chronic alcohol abuse and/or illegal drug use.
Any clinically significant abnormal laboratory finding.
A positive pregnancy test for all women of childbearing potential.
Administration of immunosuppressive drugs or other immune modifying drugs within 4 weeks prior to study enrollment.
Acute or chronic clinically significant pulmonary disease, cardiovascular disease, gastrointestinal disease, liver disease, neurological illness, liver disease, blood disease, skin disorder, endocrine disorder, neurological illness and psychiatric disorder as determined by medical history, physical examination or clinical laboratory screening tests, which in the opinion of the investigator, might interfere with the study objectives.
History of leukemia or any other blood or solid organ cancer.
Seropositive for HIV, hepatitis B surface antigen and/or hepatitis C antibodies.
Receipt of antivirals, antibiotics, immunoglobulins or other blood products within 4 weeks prior to study enrollment or planned receipt of such products during the period of subject participation in the study.
Participation in another clinical trial within the previous three months or planned enrollment in such a trial during the period of this study.
Subjects who are, in the opinion of the investigator, at significantly increased risk of non-cooperation with requirements of the study protocol.
All locations for NCT03028116
Kazakh National Medical University
Almaty, Kazakhstan, 050000
View full eligibility
Tris trial is registered with FDA with number: NCT03028116. The sponsor of the trial is Research Institute for Biological Safety Problems and it is looking for 44 volunteers for the current phase.
Official trial title: A Randomized, Blinded, Placebo-controlled Study of Phase I Allantoic Split Inactivated Seasonal Influenza Vaccine in Healthy Adults
Thank you for applying!
We'll contact you soon with more information.
FindMeCure is constantly improving its search. Take part in it and help millions by filling our patients' survey!